Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POSTERITY
2023-505825-15-00Phase 2Authorised
- Sponsor
- Roche
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial of obinutuzumab in lupus nephritis (LN) (3 arms), sponsored by Roche. Primary endpoints: Proportion of participants who achieve a complete renal response (CRR) at Week 76 (adolescent population) and Safety and pharmacokinetics through Week 76 (pediatric population). Planned start Aug 2024; status: authorised.
02
Drugs
obinutuzumab
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on 2023-505825-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505825-15-00.